A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Inclusion Criteria:

1. The patient volunteered to participate in the study and signed the Informed Consent;

2. Age, 18-70 years (include 18 and 70), male or female;

3. Expected survival ≥ 12 weeks

4. Eastern Cooperative Oncology Group score 0-2

5. CD19 or CD20 positive B-Non-Hodgkin's lymphoma confirmed by cytology or histologyaccording to World Health Organization 2016 criteria;

6. Patients with a clear diagnosis of relapsed and/or refractory B-Non-Hodgkin'slymphoma, including Diffuse Large B Cell Lymphoma, Follicular Lymphoma and MantleCell Lymphoma. Diffuse Large B Cell Lymphoma includes the following types:

7. Diffuse Large B Cell Lymphoma, Non Specifically

8. Primary Mediastinal B-cell Lymphoma

9. Transformed Follicular Lymphoma

10. High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

11. High Grade B-Cell Lymphoma, Non Specifically

12. For CD20-positive subjects, they should have received at least one regimencontaining anti-CD20-targeted therapy (such as rituximab). If they do not completethe regimen due to intolerance, the cause of intolerance should be recorded;

13. No contraindications of apheresis.

14. At least one measurable lesion according to Lugano 2014 criteria;

15. Adequate organ function and adequate bone marrow reserve

16. Hemoglobin≥80 g/L

17. Absolute neutrophil count≥1.0×109/L

18. Platelet≥50×109/L,

19. Creatinine≤1.5×upper limit of the normal range (ULN)

20. Cardiac ejection fraction≥50%

21. Saturation of Pulse Oxygen>92%

22. Total bilirubin≤1.5×ULN

23. Alanine Aminotransferase/Aspartate Aminotransferase≤3×ULN

Exclusion Criteria:

1. Malignant tumors other than B-Non-Hodgkin's lymphoma within 5 years prior toscreening, except cervical carcinoma in situ, basal cell or squamous cell skincancer, local prostate cancer after radical surgery, and breast ductal carcinoma insitu after radical surgery;

2. Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus or treponemapallidum infection ;

3. Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease needtreatment;

4. Female subjects who have been pregnant or breastfeeding, or who plan to conceiveduring or within 1 year after treatment, or male subjects' partner plans to conceivewithin 1 year after their cell transfusion;

5. Active or uncontrolled infections requiring systemic treatment within 14 days beforeenrollment;

6. Patients who have been previously infected with tuberculosis;

7. Administered Corticosteroids and/or other immunosuppressants within 7 days beforeapheresis. and 5 days before the infusion of C-CAR039;

8. Patients with central nervous system involvement;